Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Recurrence 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Endometrial Neoplasms 1Disease 1DLBCL 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma 1Advanced Solid Malignancies 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

vistusertib 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × DLBCL × vistusertib × Clear all
NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Acerta Pharma BV

Phase 1/2 Terminated
25 enrolled 11 charts
Lymphoid

DLBCL

Data powered by HemOnc (CC BY 4.0) Colophon âš¡